Satoreotide trizoxetan | CAS#1638746-88-9 | imaging agent

MedKoo Cat#: 125274 | Name: Satoreotide trizoxetan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Satoreotide trizoxetan is an imaging agent.

Chemical Structure

Satoreotide trizoxetan

CAS#1638746-88-9

Theoretical Analysis

MedKoo Cat#: 125274

Name: Satoreotide trizoxetan

CAS#: 1638746-88-9

Chemical Formula: C73H95ClN18O21S2

Exact Mass: 1658.6000

Molecular Weight: 1660.24

Elemental Analysis: C, 52.81; H, 5.77; Cl, 2.14; N, 15.19; O, 20.24; S, 3.86

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Satoreotide trizoxetan; NODAGA-JR11; Ops202; JR-11-NODAGA; Satoreotide trizoxetan [INN]

IUPAC/Chemical Name

2,2'-(7-(4-(((S)-1-(((4R,7S,10S,13R,16S,19S)-4-(((R)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl)-10-(4-aminobutyl)-16-(4-((S)-2,6-dioxohexahydropyrimidine-4-carboxamido)benzyl)-7-((R)-1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-3-(4-chlorophenyl)-1-oxopropan-2-yl)amino)-1-carboxy-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid

InChi Key

MDDXVKPIPNUPBG-FDKGEFSASA-N

InChi Code

InChI=1S/C73H95ClN18O21S2/c1-39(93)61-70(109)86-55(68(107)82-49(62(76)101)30-43-11-19-47(94)20-12-43)38-115-114-37-54(85-65(104)50(31-40-5-13-44(74)14-6-40)80-57(95)22-21-56(71(110)111)92-28-26-90(35-59(97)98)24-25-91(27-29-92)36-60(99)100)69(108)84-52(33-41-7-15-45(16-8-41)78-64(103)53-34-58(96)88-73(113)87-53)67(106)83-51(32-42-9-17-46(18-10-42)79-72(77)112)66(105)81-48(63(102)89-61)4-2-3-23-75/h5-20,39,48-56,61,93-94H,2-4,21-38,75H2,1H3,(H2,76,101)(H,78,103)(H,80,95)(H,81,105)(H,82,107)(H,83,106)(H,84,108)(H,85,104)(H,86,109)(H,89,102)(H,97,98)(H,99,100)(H,110,111)(H3,77,79,112)(H2,87,88,96,113)/t39-,48+,49-,50+,51-,52+,53+,54-,55+,56?,61+/m1/s1

SMILES Code

[H][C@]2(CC1=CC=C(NC(N)=O)C=C1)NC(=O)[C@H](CC3=CC=C(NC(=O)[C@@H]4CC(=O)NC(=O)N4)C=C3)NC(=O)[C@@H](CSSC[C@H](NC(=O)[C@@]([H])(NC(=O)[C@H](CCCCN)NC2=O)[C@@H](C)O)C(=O)N[C@H](CC5=CC=C(O)C=C5)C(N)=O)NC(=O)[C@H](CC6=CC=C(Cl)C=C6)NC(=O)CCC(N7CCN(CC(O)=O)CCN(CC(O)=O)CC7)C(O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,660.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Virgolini I, Bahri S, Kjaer A, Grønbæk H, Iversen P, Carlsen EA, Loft M, Knigge U, Maffey-Steffan J, Powell C, Miller CG, Rohban T, McEwan S, Czernin J. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for ⁶⁸Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. J Nucl Med. 2022 Mar;63(3):376-383. doi: 10.2967/jnumed.121.261936. Epub 2021 Jul 2. PMID: 34215673; PMCID: PMC8978200. 2: Miller CG, Grønbæk H, Virgolini I, Kjaer A, Terve P, Bahri S, Iversen P, Svirydenka H, Rohban T, McEwan S. A novel read methodology to evaluate the optimal dose of ⁶⁸Ga-satoreotide trizoxetan as a PET imaging agent in patients with gastroenteropancreatic neuroendocrine tumours: a phase II clinical trial. EJNMMI Res. 2021 Sep 6;11(1):84. doi: 10.1186/s13550-021-00819-1. PMID: 34487283; PMCID: PMC8421477. 3: Kersting D, Sandach P, Sraieb M, Wiesweg M, Metzenmacher M, Darwiche K, Oezkan F, Bölükbas S, Stuschke M, Umutlu L, Nader M, Hamacher R, Fendler WP, Wienker J, Eberhardt WEE, Schuler M, Herrmann K, Hautzel H. ⁶⁸Ga- SSO-120 PET for Initial Staging of Small Cell Lung Cancer Patients: A Single- Center Retrospective Study. J Nucl Med. 2023 Oct;64(10):1540-1549. doi: 10.2967/jnumed.123.265664. Epub 2023 Jul 20. PMID: 37474272.